Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.

 

Read the updated Must-Read article collection!

From the Current Issue

  • Research Articles | AuthorChoice
    Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
    Dylan J. Drakes, Sarwish Rafiq, Terence J. Purdon, Andrea V. Lopez, Smita S. Chandran, Christopher A. Klebanoff and Renier J. Brentjens
    Cancer Immunol Res June 1 2020 8 (6) 743-755; DOI:10.1158/2326-6066.CIR-19-0910

    Tumor-directed T cells function better when expressing IL18 rather than IL12. TCR-modified T cells secreting IL18 eradicate established tumors in syngeneic models in combination with sublethal irradiation and in xenograft models, providing evidence to support IL18-boosted T-cell clinical trials.

  • Research Articles
    Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
    Patricia E. de Almeida, Judy Mak, Genevive Hernandez, Rajiv Jesudason, Aurelie Herault, Vincent Javinal, Jovencio Borneo, Jeong M. Kim and Kevin B. Walsh
    Cancer Immunol Res June 1 2020 8 (6) 806-818; DOI:10.1158/2326-6066.CIR-19-0360

    Amplification of tumor hypoxia by anti-VEGF treatment enhances CD8+ T-cell antitumor responses through increased HIF1α activity. Combining anti-angiogenics and immunotherapeutics may be useful for the treatment of cancer.

  • Research Articles
    Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils
    ANM Nazmul H. Khan, Tiffany R. Emmons, Jerry T. Wong, Emad Alqassim, Kelly L. Singel, Jaron Mark, Brandon E. Smith, Joseph D. Tario, Kevin H. Eng, Kirsten B. Moysich, Kunle Odunsi, Scott I. Abrams and Brahm H. Segal
    Cancer Immunol Res June 1 2020 8 (6) 819-828; DOI:10.1158/2326-6066.CIR-19-0556

    A substantial proportion of cells with early-stage myeloid-derived suppressor cell (e-MDSC) surface markers in circulation and in ascites of patients with ovarian cancer are basophils. Exclusion of basophils from e-MDSC is required for prognostic and therapeutic studies.

OnlineFirst Articles

Load more
Advertisement

Back to top